Pharmaceutical Growth Markets 2013-2014: Insight and Analysis into Pharma Growth Markets - Understand Regional Drivers and Barriers to Develop a Robust Business Strategy
|出版日||ページ情報||英文 75 Pages; 18 Figures & Graphs
|医薬品の成長市場 Pharmaceutical Growth Markets 2013-2014: Insight and Analysis into Pharma Growth Markets - Understand Regional Drivers and Barriers to Develop a Robust Business Strategy|
|出版日: 2013年08月05日||ページ情報: 英文 75 Pages; 18 Figures & Graphs||
Our primary global research reveals where the opportunities lie, how to access these markets and what approaches are and aren't working for top pharma companies in these regions.
With the continued pressure on pharmaceutical companies to generate record profits and maintain growth, companies are being forced to look beyond the developed world. The problem is not new, and it continues to be discussed within the pharmaceutical community during this extended period of austerity in the developed world - but where do companies see opportunity?
China, Mexico, and Brazil are some of the largest pharmaceutical markets by revenue in the world and yet many would still regard them as 'emerging'. Companies have clearly realized this and understood it takes more than just a treatment and basic infrastructure to be successful; in fact, certain cities within these countries are starting to resemble the major cities of the developed world. However, the difference between the wealthy developed cities and the poor rural cities is vast, and understanding these nuances is a real differentiator.
This report aims to investigate the most promising regions and also uncover insights from leading professionals on those countries which have less coverage but still represent an exciting opportunity. Through this research we discovered that executives within pharma felt the next big opportunity for growth was going to come from Venezuela, Indonesia and Thailand. Each of these markets comes from a significantly lower base than those previously mentioned, and each has their risks - but if a company is able to get it right, then the rewards could be huge.
All six of the markets we have investigated offer exciting opportunities for pharma to grow, and each requires those leading the business unit to take a different approach in order to maximize the opportunity - unfortunately, one size does not fit all. Each of these markets is different, yet it is clear that two things remain constant; the need for a strong regional development plan and a realistic pricing strategy. As in developed markets, companies need to deliver value to all stakeholders, and if they can achieve this then they will unlock the true potential these markets hold.
"My impression of this report is that it is diverse and it covers the most relevant emerging regions. The best part of it is the research and insight from contributors: this is what you can't find in any other papers and there is plenty of it here."
"This study is one that has been extensively conducted by interviews of a broad range of pharma and healthcare executives from around the emerging markets. Since the majority of in-market emerging market executives are sitting in their respective countries, this report serves as a way to see through to what is happening on the other side of the globe, putting a global perspective on the wider industry."
"So much has changed in the emerging markets from what we knew just two years ago. To be successful, it is important to possess the latest intelligence to fully understand the current state of the pharmaceutical market in each of the countries, in order to develop the most appropriate strategies."